A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04072952 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 28, 2019
Last Update Posted : May 6, 2024
|
Sponsor:
Arvinas Estrogen Receptor, Inc.
Collaborator:
Pfizer
Information provided by (Responsible Party):
Arvinas Inc. ( Arvinas Estrogen Receptor, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | September 13, 2024 |
| Estimated Study Completion Date : | March 13, 2025 |